Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358449 · ClinicalTrials.gov registry record · Phase 2
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
A Phase 2 study of Oesophagitis, Eosinophilic, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT00358449 is a Phase 2 study of Oesophagitis, Eosinophilic that has completed, run by GlaxoSmithKline. The registered enrollment target is 84 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT00358449, a Phase 2 study of Oesophagitis, Eosinophilic, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
Conditions Studied
Interventions
- DRUG mepolizumab
Study Locations (20)
Indiana
- GSK Investigational Site - Evansville
- GSK Investigational Site - Indianapolis
Michigan
- GSK Investigational Site - Southfield
- GSK Investigational Site - Troy
Missouri
- GSK Investigational Site - Kansas City
- GSK Investigational Site - St Louis
Texas
- GSK Investigational Site - Dallas
- GSK Investigational Site - Dallas
Alabama
- GSK Investigational Site - Birmingham
California
- GSK Investigational Site - San Diego
Florida
- GSK Investigational Site - Tampa
Georgia
- GSK Investigational Site - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2006-09-11 |
| Est. Completion | 2008-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358449
The ClinicalTrials.gov registry entry for NCT00358449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oesophagitis, Eosinophilic appearing as the primary indexed condition, and to 1 intervention - of which mepolizumab is the first listed.
NCT00358449 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Indiana, Michigan, Missouri.
Frequently Asked Questions
What is clinical trial NCT00358449 about?
NCT00358449 is a clinical study titled "Intravenous Mepolizumab In Children With Eosinophilic Esophagitis". This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
What is the current status of trial NCT00358449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2006-09-11. Estimated completion is 2008-11-25.
What conditions does trial NCT00358449 study?
This clinical trial studies the following conditions: Oesophagitis, Eosinophilic.
What interventions are being tested in trial NCT00358449?
The interventions under investigation include: mepolizumab (DRUG).
Who is sponsoring clinical trial NCT00358449?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00358449 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.